KCKerry O. Cleveland

Kerry O. Cleveland

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kerry O. Cleveland has a total of 57 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Restriction Evaluation of Appropriate Carbapenem Therapy (REACT): A Multisite Observational Study

    by Drew A. Wells, Madison McKnight, Jessica Jaggar, Kerry O. Cleveland, Alaina DeKerlegand

    Introduction : Overuse of carbapenem antibiotics can lead to patient harm through adverse effects and further development of bacterial resistance. The purpose of this study was to investigate the sustained impact of meropenem restriction criteria on utilization volume and appropriateness. Methods : A retrospective observational study was conducted to evaluate meropenem restriction criteria among 5 adult hospitals (1 academic hospital and 4 community hospitals) in a single health system. Total meropenem days of therapy/1000 patient days (DOT/1000 PDs) and drug spending was compared before (January 2022) and after implementation (July 2023) were reviewed to investigate total impact of restriction criteria in the first year after implementation. Statistical comparisons used t tests or Mann-Whitney U tests for continuous data and chi square or Fisher’s exact tests for categorical data; significance was defined as P < 0.05. Results : A total of 161 meropenem orders were included in this study, with 61 (39%) found to be inappropriate based on approved restriction criteria. The top 3 reasons for inappropriate meropenem use were undocumented or non-anaphylactic penicillin allergies (31%), lack of qualifying resistant organism within 3 months (26%), and starting meropenem prior to completing 48 hours of empiric therapy with cefepime or piperacillin/tazobactam (23%). The median meropenem DOT/1000 PD decreased from 40.5 to 20 ( P < 0.001). Median monthly drug spend on meropenem across the hospital system decreased by 42% during the study period ( P = 0.001). Conclusions : Meropenem restriction criteria across a multi-site health system can sustainably reduce carbapenem use and associated costs, supporting their continued adoption in antimicrobial stewardship policy.

  • Three Strikes

    by Michael S. Gelfand, Athena L.V. Hobbs, Kerry O. Cleveland

    A 56-year-old female patient presented with severe abdominal pain and intra-abdominal/retroperitoneal fluid collections growing Escherichia coli and vancomycin-resistant Enterococcus faecium; oral linezolid and cefdinir were prescibed. Pancreatic enzymes, lactate, serum chemistry studies, and blood glucose were unremarkable during initial hospitalization. The patient remained afebrile and leukocytosis resolved with antibiotics. On day 37 of linezolid therapy, serum glucose was 56 mg/dL and serum bicarbonate was 17 mEq/L (normal 23–30 mEq/L). As the patient was asymptomatic, infectious disease consultants recommended cessation of antibiotics, but they were unfortunately continued on transfer to a rehabilitation facility. On day 41 of treatment, the patient became lethargic, with serial serum glucose levels 33–34 mg/dL. Serum bicarbonate was 6 mEq/L, lactate was >15 mmol/L, and blood pressure was 80/36 mm Hg. Admission blood cultures were negative. Supportive care was instituted, but the patient continued to clinically deteriorate. Computed tomography scan of the abdomen showed hepatic steatosis and no residual fluid collections or pancreatic abnormalities. The patient expired on the third day of hospitalization.


  • Rothia mucilaginosa Pneumonia in an Immunocompromised Patient

    by Michael S. Gelfand, Kerry O. Cleveland, Chinelo Animalu

    Rothia mucilaginosa is a gram-positive coccus recognized as an opportunistic pathogen capable of causing pneumonia in immunocompromised patients (Antimicrob Agents Chemother. 1995;39:268–270). The organism is often resistant to fluoroquinolones and trimethoprim/sulfamethoxazole, agents routinely used as anti-infective prophylaxis in immunocompromised individuals (Inf Dis Clin Pract. 2020;28:361–365; Infect Dis Now. 2021;51:228–235). Plasma next-generation sequencing (NGS) is increasing in clinical use to aid in diagnosis of infections in immunocompromised patients (Infect Dis (Lond). 2015;47:125–1299). A patient with advanced multiple myeloma was admitted with pneumonia. Plasma NGS initially suggested R. mucilaginosa, which was confirmed by cultures of bronchoalveolar lavage (BAL) fluid. Treatment with eravacycline led to clinical and radiographic resolution of pneumonia.


  • Open Access

    Dalbavancin utilization registry investigating value and effectiveness (DRIVE): Outcomes report on real-world use

    by Bruce M. Jones, Kerry O. Cleveland, Pedro L. Gonzalez, Urania Rappo, Todd Riccobene, Rosie D. Lyles


  • Open Access

    Residual Infusion Performance Evaluation (RIPE): A Single-Center Evaluation of Residual Volume Post-Intravenous Eravacycline Infusion

    by Alysa J. Baumann, Kerry O. Cleveland, Michael S. Gelfand, Nicholson B. Perkins Iii, Angela D. Covington, Athena L. V. Hobbs

    Intravenous (IV) drugs are administered through infusion pumps and IV administration sets for patients who are seen in healthcare settings. There are multiple areas of the medication administration process that can influence the amount of a drug a patient receives. For example, IV administration sets that deliver a drug from an infusion bag to a patient vary in terms of length and bore. In addition, fluid manufacturers report that the total acceptable volume range for a 250 mL bag of normal saline can be anywhere from 265 to 285 mL. At the institution chosen for our study, each 50 mg vial of eravacycline is reconstituted using 5 mL of diluent, and the total dose is administered as a 250 mL admixture. This single-center, retrospective, quasi-experimental study evaluated the residual medication volume after the completion of an IV eravacycline infusion in patients admitted during the pre-intervention study period compared to those in the post-intervention study period. The primary outcome of the study was to compare the residual antibiotic volume remaining in the bags following IV infusions of eravacycline before and after the implementation of interventions. The secondary outcomes included the following: comparing the amount of the drug lost in the pre- and post-intervention periods, determining whether the amount of residual volume was affected by nursing shifts (day versus night), and lastly assessing the cost of facility drug waste. On average, approximately 15% of the total bag volume was not infused during the pre-intervention period, which was reduced to less than 5% in the post-intervention period. Clinically, the average estimated amount of eravacycline discarded decreased from 13.5 mg to 4.7 mg in the pre- and post-intervention periods, respectively. Following the statistically significant results of this study, the interventions were expanded at this facility to include all admixed antimicrobials. Further studies are needed to determine the potential clinical impact when patients do not receive complete antibiotic infusions.


  • Open Access

    Leveling Up: Evaluation of IV v. PO Linezolid Utilization and Cost after an Antimicrobial Stewardship Program Revision of IV to PO Conversion Criteria within a Healthcare System

    by Jessica Jaggar, Kerry O. Cleveland, Jennifer D. Twilla, Shanise Patterson, Athena L. V. Hobbs

    The CDC’s Core Elements of an Antimicrobial Stewardship Program (ASP) lists intravenous (IV) to oral (PO) conversion as an important pharmacy-based intervention. However, despite the existence of a pharmacist-driven IV to PO conversion protocol, conversion rates within our healthcare system remained low. We aimed to evaluate the impact of a revision to the current conversion protocol on conversion rates, using linezolid as a marker due to its high PO bioavailability and high IV cost. This retrospective, observational study was conducted within a healthcare system composed of five adult acute care facilities. The conversion eligibility criteria were evaluated and revised on 30 November 2021. The pre-intervention period started February 2021 and ended November 2021. The post-intervention period was December 2021 to March 2022. The primary objective of this study was to establish if there was a difference in PO linezolid utilization reported as days of therapy per 1000 days present (DOT/1000 DP) between the pre- and post-intervention periods. IV linezolid utilization and cost savings were investigated as secondary objectives. The average DOT/1000 DP for IV linezolid decreased from 52.1 to 35.4 in the pre- and post-intervention periods, respectively (p < 0.01). Inversely, the average DOT/1000 DP for PO linezolid increased from 38.9 in the pre-intervention to 58.8 for the post-intervention period, p < 0.01. This mirrored an increase in the average percentage of PO use from 42.9 to 62.4% for the pre- and post-intervention periods, respectively (p < 0.01). A system-wide cost savings analysis showed projected total annual cost savings of USD 85,096.09 for the system, with monthly post-intervention savings of USD 7091.34. The pre-intervention average monthly spend on IV linezolid at the academic flagship hospital was USD 17,008.10, which decreased to USD 11,623.57 post-intervention; a 32% reduction. PO linezolid spend pre-intervention was USD 664.97 and increased to USD 965.20 post-intervention. The average monthly spend on IV linezolid for the four non-academic hospitals was USD 946.36 pre-intervention, which decreased to USD 348.99 post-intervention; a 63.1% reduction (p < 0.01). Simultaneously, the average monthly spend for PO linezolid was USD 45.66 pre-intervention and increased to USD 71.19 post-intervention (p = 0.03) This study shows the significant impact that an ASP intervention had on IV to PO conversion rates and subsequent spend. By revising criteria for IV to PO conversion, tracking and reporting results, and educating pharmacists, this led to significantly more PO linezolid use and reduced the overall cost in a large healthcare system.